Viridian Therapeutics, Inc. (NASDAQ: VRDN) reported Q1 EPS of ($0.87), $0.11 better than the analyst estimate of ($0.98). Revenue for the quarter came in at $70 thousand versus the consensus estimate of $52.09 thousand.

For earnings history and earnings-related data on Viridian Therapeutics, Inc. (VRDN) click here.